ALIM — Alimera Sciences Share Price
0.000.00%
Last trade - 00:00- $184.29m
- $236.91m
- $80.75m
- 14
- 41
- 70
- 37
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.99 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.28 | ||
| EV to EBITDA | 41.3 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.29% | ||
| Return on Equity | -697.34% | ||
| Operating Margin | -3.73% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 53.94 | 50.82 | 59.03 | 54.13 | 80.75 | 103.79 | 118.79 | 11.62% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.
Directors
- C. Daniel Myers NEC (67)
- Richard Eiswirth PRE (52)
- J. Phillip Jones CFO (57)
- Philip Ashman COO (56)
- David Holland SVP (57)
- James Largent LED (71)
- Erin Parsons DRC (46)
- Brian Halak IND (49)
- Garheng Kong IND (45)
- Peter Pizzo IND (54)
- John Snisarenko IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 4th, 2003
- Public Since
- April 22nd, 2010
- No. of Shareholders
- 26
- No. of Employees
- 159
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 52,354,450
- Address
- STE 290, 6120 WINDWARD PARKWAY, ALPHARETTA, 30005
- Web
- https://alimerasciences.com/
- Phone
- +1 6789905740
- Contact
- Scott Gordon
- Auditors
- Grant Thornton LLP
Upcoming Events for ALIM
Alimera Sciences Inc Annual Shareholders Meeting
Q2 2024 Alimera Sciences Inc Earnings Release
Similar to ALIM
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the Alimera Sciences share price?
As of Today at 19:01 UTC, shares in Alimera Sciences are trading at $3.52. This share price information is delayed by 15 minutes.
How has the Alimera Sciences share price performed this year?
Shares in Alimera Sciences last closed at $3.52 and the price had moved by +79.69% over the past 365 days. In terms of relative price strength the Alimera Sciences share price has outperformed the S&P500 Index by +45.12% over the past year.
What are the analyst and broker recommendations for Alimera Sciences?
The overall consensus recommendation for Alimera Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Alimera Sciences dividend yield?
Alimera Sciences does not currently pay a dividend.
Does Alimera Sciences pay a dividend?
Alimera Sciences does not currently pay a dividend.
When does Alimera Sciences next pay dividends?
Alimera Sciences does not currently pay a dividend.
How do I buy Alimera Sciences shares?
To buy shares in Alimera Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Alimera Sciences?
As of the previous close price of $3.52, shares in Alimera Sciences had a market capitalisation of $184.29m.
Where are Alimera Sciences shares listed?
Here are the trading details for Alimera Sciences:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ALIM
What kind of share is Alimera Sciences?
Based on an overall assessment of its quality, value and momentum Alimera Sciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Alimera Sciences share price forecast for 2024?
The analyst consensus target price for shares in Alimera Sciences is $8.00. That is 127.27% above the last closing price of $3.52.
Analysts covering Alimera Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.05 for the next financial year.
What is the trend in the Alimera Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alimera Sciences. Over the past six months, its share price has outperformed the S&P500 Index by +14.25%.
As of the last closing price of $3.52, shares in Alimera Sciences were trading +0.63% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Alimera Sciences PE Ratio?
The Alimera Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.52.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Alimera Sciences?
Alimera Sciences' management team is headed by:
- C. Daniel Myers - NEC
- Richard Eiswirth - PRE
- J. Phillip Jones - CFO
- Philip Ashman - COO
- David Holland - SVP
- James Largent - LED
- Erin Parsons - DRC
- Brian Halak - IND
- Garheng Kong - IND
- Peter Pizzo - IND
- John Snisarenko - IND